President Trump has nominated physician Heidi Overton to serve as the next commissioner of the U.S. Food and Drug Administration, positioning her at the center of major health policy decisions. The selection follows a White House announcement describing Overton as a “rockstar” with credentials described by Health Secretary Kennedy as “always right.”
Overton, a board-certified physician in public health and general preventive medicine, earned her medical degree from the University of New Mexico and a doctorate in clinical investigation from Johns Hopkins University. She served as a White House fellow during Trump’s first term, later became chief policy officer at the America First Policy Institute, and returned to the administration as a senior domestic-policy official.
The nomination places Overton directly in charge of an FDA grappling with unresolved disputes over COVID-19 vaccines, antidepressants, vaping products, rare-disease drugs, and ultra-processed foods following former Commissioner Dr. Marty Makary’s resignation in May. The agency faces immediate pressure to implement new rules requiring manufacturers to notify the FDA about ingredient safety determinations and finalize a federal definition of ultra-processed foods—a category comprising nearly 60 percent of the American diet according to HHS estimates.
Overton has also been vocal in advancing the administration’s efforts to revise childhood-vaccine recommendations, urging states to adopt new guidelines for school enrollment. Her stance on abortion medications—including advocacy for in-person evaluations and restrictions on mail-delivered mifepristone—has drawn significant scrutiny from Democratic senators and abortion advocates. U.S. Senator Bill Cassidy, chairman of the Senate committee overseeing the nomination, raised concerns about her managerial experience and leadership capacity for an agency facing staffing and morale challenges.
The White House has emphasized Overton’s deep involvement in shaping health policy throughout Trump’s administration, with Kennedy stating the selection represents “the best person” among a “pantheon of superstar candidates.” Industry analysts and advocacy groups remain divided on her fit for the role, with some criticizing her alignment with the administration’s medication-abortion policies while others view her as a trusted ally.
The confirmation hearing will test whether the Senate can reconcile Overton’s policy record with the operational demands of leading the FDA—a position that has become increasingly contentious as Washington seeks to balance medical innovation, public health protections, and evolving regulatory frameworks.
